NO20090135L - Polymorfer av N-hydroksy-3-[4-[[[-(2-metyl-1H-indol-3-yl)etyl]amino]metyl]fenyl]2E-2-propenamid - Google Patents

Polymorfer av N-hydroksy-3-[4-[[[-(2-metyl-1H-indol-3-yl)etyl]amino]metyl]fenyl]2E-2-propenamid

Info

Publication number: NO20090135L
Authority: NO; Norway
Prior art keywords: methyl; indol; hydroxy; phenyl; ethyl
Prior art date: 2006-06-12

Application number

NO20090135A

Other languages

English (en)

Norwegian (no)

Inventor

Joel Slade

Piotr Karpinski

Dimitris Papoutsakis

Joginder S Bajwa

Frank Stowasser

Murat Acemoglu

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-06-12

Filing date

2009-01-09

Publication date

2009-03-12

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38832679&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20090135(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-01-09 Application filed by Novartis Ag filed Critical Novartis Ag

2009-03-12 Publication of NO20090135L publication Critical patent/NO20090135L/no

Links

-1 2-methyl-1H-indol-3-yl Chemical group 0.000 title 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 title 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 title 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 title 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 title 1
239000012458 free base Substances 0.000 abstract 1
FPOHNWQLNRZRFC-ZHACJKMWSA-N panobinostat Chemical compound CC=1NC2=CC=CC=C2C=1CCNCC1=CC=C(\C=C\C(=O)NO)C=C1 FPOHNWQLNRZRFC-ZHACJKMWSA-N 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/20—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C07D209/16—Tryptamines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Indole Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Epidemiology (AREA)

NO20090135A 2006-06-12 2009-01-09 Polymorfer av N-hydroksy-3-[4-[[[-(2-metyl-1H-indol-3-yl)etyl]amino]metyl]fenyl]2E-2-propenamid NO20090135L (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US80451706P	2006-06-12	2006-06-12
US88322407P	2007-01-03	2007-01-03
PCT/US2007/070561 WO2007146716A2 (en)	2006-06-12	2007-06-07	Polymorphs of n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide

Publications (1)

Publication Number	Publication Date
NO20090135L true NO20090135L (no)	2009-03-12

Family

ID=38832679

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20090135A NO20090135L (no)	2006-06-12	2009-01-09	Polymorfer av N-hydroksy-3-[4-[[[-(2-metyl-1H-indol-3-yl)etyl]amino]metyl]fenyl]2E-2-propenamid

Country Status (29)

Country	Link
US (1)	US7989494B2 (es)
EP (2)	EP2409967A1 (es)
JP (3)	JP2009540006A (es)
KR (4)	KR20160032264A (es)
CN (1)	CN102584673B (es)
AR (1)	AR061297A1 (es)
AU (1)	AU2007257881B2 (es)
BR (1)	BRPI0712993A2 (es)
CA (1)	CA2650263A1 (es)
CL (1)	CL2007001689A1 (es)
CR (1)	CR10440A (es)
EA (1)	EA017984B1 (es)
EC (1)	ECSP088976A (es)
GE (1)	GEP20115175B (es)
GT (1)	GT200800280A (es)
IL (1)	IL195015A (es)
MA (1)	MA30511B1 (es)
ME (1)	ME00529B (es)
MX (1)	MX2008015900A (es)
MY (1)	MY149337A (es)
NI (1)	NI200800306A (es)
NO (1)	NO20090135L (es)
PE (1)	PE20080852A1 (es)
PH (2)	PH12012501724A1 (es)
SM (1)	SMP200900001B (es)
TN (1)	TNSN08495A1 (es)
TW (2)	TWI515179B (es)
UY (1)	UY30406A1 (es)
WO (1)	WO2007146716A2 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SMP200900002B (it) *	2006-06-12	2010-01-19	Novartis Ag	Sali di n-idrossi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]ammino]metil]fenil]-2e-2-propenammide
AU2008204928B2 (en) *	2007-01-10	2011-03-31	Novartis Ag	Formulations of deacetylase inhibitors
WO2017032281A1 (zh) *	2015-08-21	2017-03-02	苏州晶云药物科技有限公司	帕比司他乳酸盐的新晶型
CN106866492B (zh) *	2015-12-10	2021-11-26	江苏豪森药业集团有限公司	帕比司他乳酸盐晶型ii及其制备方法和用途
CN106866491B (zh) *	2015-12-10	2021-12-10	江苏豪森药业集团有限公司	帕比司他乳酸盐晶型ⅰ及其制备方法和用途
WO2018092151A1 (en) *	2016-11-21	2018-05-24	Msn Laboratories Private Limited, R&D Center	Process for the preparation of 2-(e)-n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl) ethyl]amino]methyl]phenyl]-2-propenamide 2-hydroxypropanoic acid (1:1) and its polymorphs thereof
WO2018163114A1 (en) *	2017-03-10	2018-09-13	Shilpa Medicare Limited	Amorphous panobinostat and its lactate salt
US10537585B2 (en)	2017-12-18	2020-01-21	Dexcel Pharma Technologies Ltd.	Compositions comprising dexamethasone
EP4019496B1 (en) *	2019-08-20	2024-06-05	ONO Pharmaceutical Co., Ltd.	Salt and crystal form of compound having agonistic activity to s1p5 receptor
GB201913122D0 (en)	2019-09-11	2019-10-23	Seald As	Compositions and methods for treatment of cholangiocarcinoma
GB201913121D0 (en)	2019-09-11	2019-10-23	Seald As	Compositions and methods for treatment of cholangiocarcinoma
GB201913124D0 (en)	2019-09-11	2019-10-23	Seald As	Compositions and methods for treatment of cholangiocarcinoma
CN116648449A (zh) *	2020-10-28	2023-08-25	维拉克塔附属公司	Hdac抑制剂固态形式

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PE20020354A1 (es) *	2000-09-01	2002-06-12	Novartis Ag	Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
NZ544689A (en)	2001-11-06	2007-08-31	Novartis Ag	Cyclooxygenase-2 inhibitor/histone deacetylase inhibitor combination
AU2002361022A1 (en)	2001-12-07	2003-06-17	Novartis Ag	Use of alpha-tubulin acetylation levels as a biomarker for protein deacetylase inhibitors
WO2004103358A2 (en)	2003-05-21	2004-12-02	Novartis Ag	Combination of histone deacetylase inhibitors with chemotherapeutic agents
US20060270730A1 (en)	2003-08-07	2006-11-30	Andreas Katopodis	Histone deacetylase inhibitors as immunosuppressants
EA200600495A1 (ru)	2003-09-23	2006-10-27	Новартис Аг	Комбинация ингибитора vegf рецептора с химиотерапевтическим агентом
SMP200900002B (it)	2006-06-12	2010-01-19	Novartis Ag	Sali di n-idrossi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]ammino]metil]fenil]-2e-2-propenammide

2007
- 2007-06-07 MY MYPI20084896A patent/MY149337A/en unknown
- 2007-06-07 KR KR1020167006197A patent/KR20160032264A/ko not_active Ceased
- 2007-06-07 ME MEP-2008-876A patent/ME00529B/me unknown
- 2007-06-07 EP EP11183770A patent/EP2409967A1/en not_active Withdrawn
- 2007-06-07 US US12/302,564 patent/US7989494B2/en active Active
- 2007-06-07 KR KR1020147030218A patent/KR20140142335A/ko not_active Withdrawn
- 2007-06-07 SM SM200900001T patent/SMP200900001B/it unknown
- 2007-06-07 BR BRPI0712993-9A patent/BRPI0712993A2/pt not_active Application Discontinuation
- 2007-06-07 KR KR1020157017416A patent/KR20150082690A/ko not_active Withdrawn
- 2007-06-07 GE GEAP200711011A patent/GEP20115175B/en unknown
- 2007-06-07 MX MX2008015900A patent/MX2008015900A/es active IP Right Grant
- 2007-06-07 PH PH1/2012/501724A patent/PH12012501724A1/en unknown
- 2007-06-07 CN CN201210014735.0A patent/CN102584673B/zh active Active
- 2007-06-07 WO PCT/US2007/070561 patent/WO2007146716A2/en not_active Ceased
- 2007-06-07 AU AU2007257881A patent/AU2007257881B2/en not_active Ceased
- 2007-06-07 CA CA002650263A patent/CA2650263A1/en not_active Abandoned
- 2007-06-07 JP JP2009515573A patent/JP2009540006A/ja active Pending
- 2007-06-07 EA EA200802383A patent/EA017984B1/ru not_active IP Right Cessation
- 2007-06-07 EP EP07798194A patent/EP2086930A2/en not_active Withdrawn
- 2007-06-07 KR KR1020087030229A patent/KR20090015968A/ko not_active Ceased
- 2007-06-08 TW TW103124314A patent/TWI515179B/zh not_active IP Right Cessation
- 2007-06-08 PE PE2007000724A patent/PE20080852A1/es not_active Application Discontinuation
- 2007-06-08 AR ARP070102499A patent/AR061297A1/es not_active Application Discontinuation
- 2007-06-08 TW TW096120847A patent/TWI453196B/zh not_active IP Right Cessation
- 2007-06-11 CL CL200701689A patent/CL2007001689A1/es unknown
- 2007-06-11 UY UY30406A patent/UY30406A1/es not_active Application Discontinuation
2008
- 2008-10-30 IL IL195015A patent/IL195015A/en active IP Right Grant
- 2008-11-13 CR CR10440A patent/CR10440A/es not_active Application Discontinuation
- 2008-11-21 NI NI200800306A patent/NI200800306A/es unknown
- 2008-11-28 TN TNP2008000495A patent/TNSN08495A1/en unknown
- 2008-12-10 GT GT200800280A patent/GT200800280A/es unknown
- 2008-12-12 EC EC2008008976A patent/ECSP088976A/es unknown
- 2008-12-12 MA MA31470A patent/MA30511B1/fr unknown
2009
- 2009-01-09 NO NO20090135A patent/NO20090135L/no not_active Application Discontinuation
2012
- 2012-08-29 PH PH12012501725A patent/PH12012501725A1/en unknown
2013
- 2013-04-15 JP JP2013085093A patent/JP2013139476A/ja active Pending
2015
- 2015-06-24 JP JP2015127007A patent/JP2015164968A/ja active Pending

Also Published As

Publication number	Publication date
PH12012501724A1 (en)	2014-05-12
NI200800306A (es)	2012-02-01
TWI453196B (zh)	2014-09-21
JP2015164968A (ja)	2015-09-17
IL195015A0 (en)	2009-08-03
SMP200900001B (it)	2010-03-01
MX2008015900A (es)	2009-03-06
JP2009540006A (ja)	2009-11-19
CL2007001689A1 (es)	2008-05-16
AR061297A1 (es)	2008-08-20
IL195015A (en)	2014-03-31
TW200815344A (en)	2008-04-01
KR20160032264A (ko)	2016-03-23
WO2007146716A3 (en)	2009-07-30
CN102584673B (zh)	2014-08-06
GT200800280A (es)	2015-11-24
EA017984B1 (ru)	2013-04-30
CR10440A (es)	2011-08-22
CN102584673A (zh)	2012-07-18
KR20140142335A (ko)	2014-12-11
KR20090015968A (ko)	2009-02-12
US7989494B2 (en)	2011-08-02
TNSN08495A1 (en)	2010-04-14
MY149337A (en)	2013-08-30
EP2086930A2 (en)	2009-08-12
TW201441190A (zh)	2014-11-01
US20090192210A1 (en)	2009-07-30
GEP20115175B (en)	2011-03-10
ECSP088976A (es)	2009-01-30
MA30511B1 (fr)	2009-06-01
TWI515179B (zh)	2016-01-01
ME00529B (me)	2011-10-10
KR20150082690A (ko)	2015-07-15
PH12012501725A1 (en)	2015-07-06
UY30406A1 (es)	2008-01-31
AU2007257881B2 (en)	2011-06-16
PE20080852A1 (es)	2008-08-19
WO2007146716A2 (en)	2007-12-21
EA200802383A1 (ru)	2010-02-26
EP2409967A1 (en)	2012-01-25
CA2650263A1 (en)	2007-12-21
SMAP200900001A (it)	2009-01-14
AU2007257881A1 (en)	2007-12-21
JP2013139476A (ja)	2013-07-18
BRPI0712993A2 (pt)	2012-04-17

Legal Events

Date	Code	Title	Description
2019-02-11	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20090128L (no)	2009-03-11	Salter av N-hydroksy-3-[4-[[[2-(2-metyl-1H-indol-3-yl)etyl]amino]metyl]fenyl]-2E-2-propenamid
PH12012501725A1 (en)	2015-07-06	Polymorphs of n-hydroxy3-[4[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]2e-2-propenamide
NO20090136L (no)	2009-03-06	Fremgangsmate for fremstilling av salter av N-hydroksy-3-[4-[[[2-(2-metyl-1H-1ln-dol-3-yl)etyl]amino]metyl]fenyl]-2E-2-propenamid
UA95289C2 (en)	2011-07-25	Salts of n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide
UA97243C2 (en)	2012-01-25	Crystalline anhydrous form of n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide
NO20090137L (no)	2009-03-03	Fremgangsmate for fremstilling av N-hydroksy-3-[4-[[[2-(2-metyl-1H-indol-3-yl)etyl]amino]metyl]fenyl]-2E-2-propenamid og startmaterialer derav
CY1117493T1 (el)	2017-04-26	Αλατα του ν-υδροξυ-3-[4-[[[2-(2-μεθυλ-1η-ινδολ-3-υλ)αιθυλ]αμινο]μεθυλο]φαινυλο]-2ε-2-προπεναμιδιου
HK1132509A (en)	2010-02-26	Polymorphs of n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide
DOP2008000069A (es)	2009-03-31	Sales de n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]amino]metil]]fenil]-2e-2-propenamida.
DOP2008000068A (es)	2009-03-31	Polimorfos de n-hidroxi-3[4-[[[2-(2-metil-1h-indol-3-il)etil]amino]metil]fenil]-2e-2-propenamida
CU20080237A7 (es)	2011-03-21	Polimorfos de n-hidroxi-3-[4-[[[2-metil-1h-indol-3-il)etil]amino]metil]fenil]2e-2-propenamida